# Marea Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/marea-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.mareatx.com
- Latest round: Series A (Jun 18, 2024)
- Investors on record: 8

## About

Based in California, US, and co-founded by Charles Homcy, Stephen O’Rahilly, Joshua Rabinowitz, and Ethan Weiss (Chief Scientific Officer), Marea Therapeutics, Inc. operates as a biotechnology company that engages in the development of medicines for Cardiometabolic Diseases. In June 2024, Marea Therapeutics, Inc. raised USD 190 million in series A and series B funding co-led by investors Sofinnova Investments, Forbion, Perceptive Advisors, and VenBio Partners, with the participation from other investor Third Rock Ventures, Alpha Wave Global, Omega Funds, and Surveyor Capital. The firm as of June 2024, is led by its CEO, Josh Lehrer, Chief Development Operations Officer, Mark Joing, and Chief Strategy Officer, Christine Garrett.

The company combines human genetic insights with advanced adipocyte biology to target unmet medical needs in cardiovascular health. Marea Therapeutics' flagship product, MAR001, is a monoclonal antibody designed to inhibit ANGPTL4, a protein pivotal in adipose tissue function. This therapy aims to enhance lipoprotein lipase activity, thereby reducing remnant cholesterol levels and improving insulin sensitivity. The company's pipeline includes undisclosed programs targeting validated genetic markers, aiming to expand therapeutic options for metabolic dysfunction.

The company plans to utilize the June 2024 funding to hasten the development of novel therapeutics for cardiometabolic illnesses.

## Funding rounds

- Series A, Jun 18, 2024 — Third Rock Ventures
- Series B, Jun 11, 2024 — Sofinnova Investments, Forbion, Third Rock Ventures, Surveyor Capital, Omega Funds, Alpha Wave Global, VenBio, Perceptive Advisors

## Investors

- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series B, Series A
- Surveyor Capital — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B